image text translation
(1)U.S. Dementia New Drug Approval Expected to Apply Drug Price Insurance
(2)Recanemab, a new drug for dementia, targets beta-amyloid in the brain
(3)U.S. Approves New Dementia Drug
(4)Expectation of drug price insurance coverage
(5)Recanemab has a cognitive function improvement effect of 27
(6)Clinical data from Thomas Wiswisky, director of the Rangoon Alzheimer’s Research Center at New York University, shows clearly that it works and removes beta-amyloid aggregates
(7)Expectation of drug price insurance coverage
(8)U.S. FDA Validity Recognition…RECANEMAB ACCELERATION APPROVED IN JANUARY
(9)Approving New Dementia Drugs
(10)Accelerated approval Approvals before all clinical data are collected
(11)U.S. Approves New Dementia Drug
(12)Recanemab’s annual drug price is about $26,000 and KRW 33 million
(13)Approving New Drugs for Dementia
(14)Ezai also applied for lecanemab approval to the domestic FDA
(15)Beta amyloid in the brain, a causative agent in the brain that causes dementia
(16)You get dementia when you lump it together
(17)The principle of inhibiting the clumping of beta-amyloid is to prevent dementia
(18)He said he’ll cure it
(19)The existing dementia medication has only been alleviated, but this is an improvement in cognitive function
(20)It is attracting attention as a fundamental treatment
(21)The FDA determines that it is a sufficiently valid new drug, so clinical data
(22)Skip collection and approve acceleration
(23)The price of the medicine is 33 million won
(24)In Korea, approval will be decided in the second half of next year
!